<DOC>
<DOCNO>
EP-0014569
</DOCNO>
<TEXT>
<DATE>
19800820
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/4418 A61P-9/00 A61K-31/4402 A61P-9/06 <main>A61K-31/44</main> A61K-31/44 C07D-213/00 C07D-213/56 
</IPC-CLASSIFICATIONS>
<TITLE>
(-)-alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-2-pyridineacetamide and pharmacologically acceptable salts thereof, process for the production thereof and compositions containing the same.
</TITLE>
<APPLICANT>
searle & cous<sep>g.d. searle & co.<sep>g.d. searle &amp; co.p.o. box 1045skokie illinois 60076us<sep>g.d. searle & co.<sep>
</APPLICANT>
<INVENTOR>
sollman paul benjamin<sep>sollman, paul benjamin<sep>sollman, paul benjamin2040 old glenview roadwilmetter, illinoisus<sep>sollman, paul benjamin<sep>sollman, paul benjamin2040 old glenview roadwilmetter, illinoisus<sep>
</INVENTOR>
<ABSTRACT>
(-)-α-{2 [bis(1-methylethyl) amino]ethyl}-α-phenyl­ -2-pyridineacetamide and pharmacologically acceptable salts  thereof.  a preferred salt is the phosphate salt.  the base has  antiarrhythmic properties and diminished or favourably  altered anitcholinergic side effects compared with its  enantiomer or a racemic mixture.  preparation of the base is  via resolution of the racemic mixture.  
</ABSTRACT>
</TEXT>
</DOC>
